Resistance to Cefiderocol Involved Expression of PER-1 β-Lactamase and Downregulation of Iron Transporter System in Carbapenem-Resistant Acinetobacter baumannii
Yukun He,Yifan Wang,Xinqian Ma,Lili Zhao,Jie Guan,Jin Zhao,Wenyi Yu,Yanjun Li,Wentao Ni,Zhancheng Gao
DOI: https://doi.org/10.2147/IDR.S392241
2022-12-07
Infection and Drug Resistance
Abstract:Yukun He, 1, &ast Yifan Wang, 1, &ast Xinqian Ma, 1 Lili Zhao, 1 Jie Guan, 2 Jin Zhao, 3 Wenyi Yu, 1 Yanjun Li, 4 Wentao Ni, 1 Zhancheng Gao 1 1 Department of Pulmonary and Critical Care Medicine, Peking University People's Hospital, Beijing, People's Republic of China; 2 Clinical Laboratory, Peking University First Hospital, Beijing, People's Republic of China; 3 Department of Respiratory Diseases, Air Force Medical Center, Chinese People's Liberation Army, Beijing, People's Republic of China; 4 Clinical Laboratory, The Sixth Medical Center of PLA General Hospital, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wentao Ni; Zhancheng Gao, Department of Pulmonary and Critical Care Medicine, Peking University People's Hospital, Beijing, People's Republic of China, Email ; Background: Cefiderocol (CFDC) is a promising antimicrobial agent against multidrug resistant Gram-negative bacteria. However, CFDC resistance has emerged in carbapenem-resistant Acinetobacter baumannii (CR-AB) but the underlying mechanisms remain unclear. Methods: Whole-genome sequencing and transcriptome sequencing were performed on CFDC-non-susceptible and CFDC-susceptible isolates. Two different recombinant plasmids was electro-transformed into the E. coli BL21 strain to determine the impact of bla PER and the combined impact of bla PER-1 and bla OXA-23 on CFDC resistance. Results: Fifty-five CR-AB isolates with minimum inhibitory concentrations (MICs) ranged from 0.06 mg/L to > 256 mg/L were sequenced, including 47 CFDC-non-susceptible and eight CFDC-susceptible isolates. Two CFDC-non-susceptible isolates belonged to ST104 whereas the remaining isolates belonged to ST2, and bla PER-1 was present only in CFDC-non-susceptible isolates. Amino acid substitutions were noted in penicillin-binding proteins (PBPs) in four CFDC-susceptible isolates, with slightly elevated MICs. The MICs of recombinant E. coli BL21 carrying the bla PER-1 gene increased 64-fold and recombinant E. coli BL21 carrying both the bla PER-1 and bla OXA-23 genes increased 8-fold but both remained within the susceptibility range. Transcriptome sequencing of 17 CFDC-non-susceptible isolates and eight CFDC-susceptible isolates revealed that transcriptional levels of various iron transport proteins, such as fiu, feoA , and feoB , and the energy transduction system, TonB-ExbB-ExbD, were relatively downregulated in CFDC-non-susceptible isolates. GO enrichment analysis revealed that the upregulated genes in CFDC-non-susceptible isolates were mainly associated with redox homeostasis and stress response. Besides, the expression levels of the bla OXA-23 and exbD genes were negatively correlated with the MICs. Conclusion: PER-1 production, iron transport system downregulation, and mutations in PBPs may synergistically impart high-level resistance to CFDC in CR-AB. Keywords: carbapenem-resistant Acinetobacter baumannii , cefiderocol resistance, bla PER-1 , iron transporter systems Cefiderocol (CFDC) is a novel siderophore-cephalosporin that was approved successively by the United States Food and Drug Administration (FDA) and European Medicines Agency for treating complicated gram-negative infections in 2019 and 2020. 1 The catechol side chain of CFDC readily complexes with ferric iron, allowing it to utilize an iron-based transport system to penetrate the bacterial outer membrane. This "Trojan horse" strategy allows more drugs to enter the bacterial periplasmic space and bind to penicillin-binding proteins (PBPs), interfering with cell wall synthesis and ultimately causing bacterial death. 2 Susceptibility surveillance has revealed the potent activity of CFDC against a wide range of carbapenem-resistant gram-negative bacteria (CR-GNB), including isolates of Acinetobacter baumannii, Enterobacterales , and Pseudomonas aeruginosa . 3 The CREDIBLE-CR trial showed that the clinical and microbiological efficacy of CFDC was comparable to that of the best available therapeutic agents for various CR-GNB infections. 4 However, resistance to CFDC has emerged among CR-GNB before its widespread use in clinical practice. For example, the SIDERO-CR-2014/2016 surveillance study identified 72 CFDC-non-susceptible isolates from 1873 carbapenem non-susceptible isolates, and the European test set of th -Abstract Truncated-
pharmacology & pharmacy,infectious diseases